NEW YORK (GenomeWeb) – Meridian Bioscience today reported a 1 percent decline in revenues for its fiscal third quarter. 

For the three months ended June 30, Meridian posted $50.1 million in revenues, down from $50.7 million in the year-ago period but above the consensus Wall Street estimate of $49.2 million. 

The company's life science segment saw revenues grow 8 percent to $14.2 million from $13.1 million, while the diagnostics segment saw a 4 percent decline in revenues to $35.9 million from $37.5 million. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The UK's Nuffield Council on Bioethics says genetically modifying human embryos could be morally permissible, according to the Guardian.

A new Nature Biotechnology paper reports that CRISPR-Cas9 gene editing can lead to large deletions or complex rearrangements that could be pathogenic.

The Wall Street Journal likens a prototype developed by Synthetic Genomics to a "biological fax machine."

In PNAS this week: strategy for reactivating Rett syndrome-linked MECP2, small molecules able to suppress Staphylococcus aureus virulence, and more.